跳至主要内容
临床试验/NCT03188900
NCT03188900已完成不适用

New Therapeutic Strategy Against Preeclampsia: Angiogenic Switch to Physiological State by Extracorporeal Removal of sFlt-1

Assistance Publique - Hôpitaux de Paris1 个研究点 分布在 1 个国家目标入组 236 人开始时间: 2017年6月12日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
236
试验地点
1
主要终点
ratio sFlt-1/PlGF

研究概览

简要总结

The aim of the study is to setup a collection of maternal plasma and serum from patients with preeclampsia and normal pregnancy for in vitro validation of new therapeutics based on extra-corporal removal of sFlt-1

详细描述

A collection of maternal plasma and serum from patients with preeclampsia (PE) and normal pregnancy (NP) :

  • Between 20WG and 23WG+6D : 20 patients with PE and 30 patients with NP
  • Between 24WG and 27WG+6D : 20 patients with PE and 30 patients with NP
  • Between 28WG and 31WG+6D : 20 patients with PE and 30 patients with NP
  • Between 32WG and 35WG+6D : 20 patients with PE and 30 patients with NP
  • Between 36WG and 40WG+6D : 20 patients with PE and 30 patients with NP

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Age from 18 to 50 years old
  • Singleton pregnancies between 20 and 41 weeks of gestation
  • Preeclampsia
  • Normal pregnancy

排除标准

  • Infectious disease: HIV, HBV or HCV
  • Multiple pregnancies
  • Opposition of the patient

结局指标

主要结局

ratio sFlt-1/PlGF

时间窗: Day 0

measurement of of sFlT-1 and PlGF

次要结局

  • Kinetics of these ratios sFlt-1/PlGF during pregnancy(until 5 month)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验